콘텐츠로 건너뛰기
Merck
모든 사진(1)

문서

SML2263

Sigma-Aldrich

Ladostigil tartrate

≥98% (HPLC)

동의어(들):

(3R)-(N-Propargylaminoindan-5-yl)-ethyl methyl carbamate tartrate (2:1), TV-3326, TV3326

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C16H20N2O2 · 0.5C4H6O6
CAS Number:
Molecular Weight:
347.39
MDL number:
UNSPSC 코드:
12352200

분석

≥98% (HPLC)

형태

powder

저장 조건

desiccated

색상

white to beige

solubility

H2O: 2 mg/mL, clear

저장 온도

2-8°C

InChI

1S/2C16H20N2O2.C4H6O6/c2*1-4-10-17-15-9-7-12-6-8-13(11-14(12)15)20-16(19)18(3)5-2;5-1(3(7)8)2(6)4(9)10/h2*1,6,8,11,15,17H,5,7,9-10H2,2-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t2*15-;1-,2-/m111/s1

InChI key

PRLVBVAJMQZMJN-OGOSNNLPSA-N

생화학적/생리학적 작용

Ladostigil, a carbamate is also a butyryl cholinesterase (BuChE) inhibitor. It possesses anti-inflammatory property and effectively reduces the levels of tumor necrosis factor α (TNF-α) in lipopolysaccharide (LPS)-activated macrophages. It provides protection to cardiomyocytes. Ladostigil has neuroprotective functionality and has the potential to treat mild cognitive impairment (MCI) and spatial memory deficits development. It also exhibits protective effects during oxidative and nitrative stress.
Multifunctional drug designed to treat Alzhemier′s disease by combining in a single molecule the neuroprotective/neurorestorative effects of the (MAO)-B inhibitor rasagiline with the cholinesterase (ChE) inhibitory activity of rivastigmine.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Rony Panarsky et al.
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 7(2), 488-498 (2012-03-29)
Impaired mitochondrial function accompanied by microglial activation and the release of nitric oxide (NO) and pro-inflammatory cytokines has been reported in Alzheimer's disease, its prodromal phase of Mild Cognitive Impairment (MCI) and in aged rats. The present study showed that
Orly Weinreb et al.
British journal of pharmacology, 173(13), 2080-2094 (2015-09-04)
Alzheimer's disease (AD) is accepted nowadays as a complex neurodegenerative disorder with multifaceted cerebral pathologies, including extracellular deposition of amyloid β peptide-containing plaques, intracellular neurofibrillary tangles, progressive loss of cholinergic neurons, metal dyshomeostasis, mitochondrial dysfunction, neuroinflammation, glutamate excitoxicity, oxidative stress
John P M Finberg et al.
Frontiers in pharmacology, 7, 340-340 (2016-11-03)
Inhibitors of MAO-A and MAO-B are in clinical use for the treatment of psychiatric and neurological disorders respectively. Elucidation of the molecular structure of the active sites of the enzymes has enabled a precise determination of the way in which
Moussa B H Youdim
Experimental neurobiology, 22(1), 1-10 (2013-04-16)
Present anti-PD and -AD drugs have limited symptomatic activity and devoid of neuroprotective and neurorestorative property that is needed for disease modifying action. The complex pathology of PD and AD led us to develop several multi-target neuroprotective and neurorestorative drugs
Inessa Yanovsky et al.
Journal of medicinal chemistry, 55(23), 10700-10715 (2012-11-16)
The cascade of events that occurs in Alzheimer's disease involving oxidative stress and the reduction in cholinergic transmission can be better addressed by multifunctional drugs than cholinesterase inhibitors alone. For this purpose, we prepared a large number of derivatives of

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.